Wang Yanli, Bai Liang, Lin Yan, Chen Yulong, Guan Hua, Zhu Ninghong, Li Yafeng, Gao Shoucui, Sun Lijing, Zhao Sihai, Fan Jianglin, Liu Enqi
Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University Cardiovascular Research Center, Xi'an, Shaanxi, 710061, China.
Department of Pathology, Xi'an Medical University, Xi'an, Shaanxi, 710021, China.
Lipids Health Dis. 2015 Jul 29;14:82. doi: 10.1186/s12944-015-0083-5.
Atherosclerotic cardiovascular disease is one of the major diseases that seriously impacts human health. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events.
The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits.
Thirty Japanese white rabbits were fed with a high cholesterol diet for 12 weeks, which was supplemented with either 0.005% atorvastatin alone or 0.005% atorvastatin plus 0.3% probucol and 0.3% cilostazol. Except for high-density lipoprotein cholesterol, no difference was found in plasma lipids among vehicle, statin, and the combined treatment group. However, atherosclerotic lesions were significantly reduced by statin treatment compared with vehicle. Moreover, we found that the anti-atherogenic effect of statin was further enhanced by the combined treatment, which was due to increased anti-inflammatory and anti-oxidant properties.
These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect.
动脉粥样硬化性心血管疾病是严重影响人类健康的主要疾病之一。联合药物治疗可能有效延缓心血管事件的发生。
本研究旨在探讨普罗布考（一种抗氧化剂）与西洛他唑（一种血小板聚集抑制剂）联合使用是否会增强他汀类药物（一种降脂药）对中度高胆固醇血症兔动脉粥样硬化的抑制作用。
30只日本白兔接受高胆固醇饮食12周，分别单独补充0.005%阿托伐他汀或0.005%阿托伐他汀加0.3%普罗布考和0.3%西洛他唑。除高密度脂蛋白胆固醇外，载体组、他汀组和联合治疗组之间的血脂无差异。然而，与载体组相比，他汀治疗显著减少了动脉粥样硬化病变。此外，我们发现联合治疗进一步增强了他汀的抗动脉粥样硬化作用，这是由于抗炎和抗氧化特性增强。
这些数据表明，联合药物治疗通过多效性功能，如抗炎和抗氧化应激，表现出强大的动脉粥样硬化保护作用，这与降脂作用无关。
